Aeterna Zentaris Inc.

Equities

AEZS

CA0079755017

Biotechnology & Medical Research

Delayed Toronto S.E. 12:40:46 2024-03-28 pm EDT 5-day change 1st Jan Change
2.94 CAD +3.89% Intraday chart for Aeterna Zentaris Inc. +2.19% +8.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share MT
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stocks Edge -2- DJ
North American Morning Briefing : Markets on Hold -2- DJ
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co MT
Traders Search for Fresh Cues After Fed-Driven Rally as US Equity Futures Waver Pre-Bell MT
Top Premarket Gainers MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co MT
Aeterna Zentaris Inc. entered into a definitive agreement to acquire Ceapro Inc. for CAD 20 million in a merger of equals transaction. CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs DJ
HC Wainwright Cuts Aeterna Zentaris' Price Target to $15 From $28, Maintains Buy Rating MT
Aeterna Zentaris Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Traders Await -2- DJ
North American Morning Briefing : China Angst -2- DJ
Aeterna Zentaris Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Aeterna Zentaris Brief: Ended Q2 with US$42.2 million in cash, expected to fund operations into 2025 MT
Aeterna Zentaris Brief: Reported a Q2 consolidated net loss of US$2.5 million, or $0.52 loss per common share (basic and diluted) MT
Transcript : Aeterna Zentaris Inc. - Special Call
Aeterna Zentaris Outlines "Progress" on Development Pipeline Programs and Providies Corporate Update MT
Aeterna Zentaris Brief: Outlining "Progress" on Development Pipeline Programs and Provides Corporate Update MT
Chart Aeterna Zentaris Inc.
More charts
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.83
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Aeterna Zentaris Inc. - Toronto S.E.
  4. News Aeterna Zentaris Inc.
  5. Pharmanovia to Buy License to Ghryvelin from Aeterna Zentaris' Existing Licensee, Consilient Health, Effective Immediately